NEW DELHI: The Centre has fixed the price of 71 key drug formulations, including medicines approved for treating metastatic breast cancer, allergies and diabetes, among others.
Also, the notification issued by the National Pharmaceutical Pricing Authority (NPPA) states that the manufacturer may add Goods and Services Tax (GST) only if they have paid or it is payable to the government on the retail price.
The drugs for which prices have been fixed include Trastuzumab by Reliance Life Sciences. It is used in the treatment of metastatic breast cancer and gastric cancer. The NPPA has fixed its price at Rs 11,966 per vial.
The price of a combination drug containing clarithromycin, esomeprazole and amoxicillin which is used to treat peptic ulcer disease - a sore on the lining of the stomach - manufactured by Torrent Pharmaceuticals has been fixed at Rs 162.5 per tablet.
The price of a combipack of ceftriaxone, disodium edetate and sulbactam powder used to treat life-threatening infections has been fixed at Rs 626 per vial. Another key drug combination used for treating infections containing ceftriaxone, disodium edetate and sulbactam powder for solution for Infusion from Tyykem has been priced at Rs 515.5 per vial, according to the NPPA notification.
The NPPA has also notified the retail price of 25 anti-diabetes formulations containing sitagliptin as a component, apart from several other antidiabetic formulations containing empagliflozin as a combination in its latest notification. NPPA, a government regulatory agency, is responsible for controlling and revising the prices of pharmaceutical products in India.
In February, the regulatory body issued an order stating that drug manufacturers must issue a price list to the dealers, state drug controllers and the government, indicating reference to such price fixation or revision as covered by the order or gazette notification issued by the government from time to time. "The order to display the price list is to allow citizens to cross-check whether the pharmacies are selling at the price fixed by NPPA or not," said an official.
"Every retailer and dealer shall display the price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carried on business in a manner so as to be easily accessible to any person wishing to consult the same," the NPPA's February order stated. It added that the directive also covers the virtual/online premises where the retailer or dealer carries on business.
Also, the notification issued by the National Pharmaceutical Pricing Authority (NPPA) states that the manufacturer may add Goods and Services Tax (GST) only if they have paid or it is payable to the government on the retail price.
The drugs for which prices have been fixed include Trastuzumab by Reliance Life Sciences. It is used in the treatment of metastatic breast cancer and gastric cancer. The NPPA has fixed its price at Rs 11,966 per vial.
The price of a combination drug containing clarithromycin, esomeprazole and amoxicillin which is used to treat peptic ulcer disease - a sore on the lining of the stomach - manufactured by Torrent Pharmaceuticals has been fixed at Rs 162.5 per tablet.
The price of a combipack of ceftriaxone, disodium edetate and sulbactam powder used to treat life-threatening infections has been fixed at Rs 626 per vial. Another key drug combination used for treating infections containing ceftriaxone, disodium edetate and sulbactam powder for solution for Infusion from Tyykem has been priced at Rs 515.5 per vial, according to the NPPA notification.
The NPPA has also notified the retail price of 25 anti-diabetes formulations containing sitagliptin as a component, apart from several other antidiabetic formulations containing empagliflozin as a combination in its latest notification. NPPA, a government regulatory agency, is responsible for controlling and revising the prices of pharmaceutical products in India.
In February, the regulatory body issued an order stating that drug manufacturers must issue a price list to the dealers, state drug controllers and the government, indicating reference to such price fixation or revision as covered by the order or gazette notification issued by the government from time to time. "The order to display the price list is to allow citizens to cross-check whether the pharmacies are selling at the price fixed by NPPA or not," said an official.
"Every retailer and dealer shall display the price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carried on business in a manner so as to be easily accessible to any person wishing to consult the same," the NPPA's February order stated. It added that the directive also covers the virtual/online premises where the retailer or dealer carries on business.
You may also like
Javed Akhtar gives session on Urdu at British Parliament, Shabana shares picture
Donald Trump throws shade at 'sloppy Brexit' - but says Starmer's sorting it out
Australian central bank proposes banning card payment surcharges
34 fishermen from Bengal's Kakdwip detained in Bangladesh
Trump's edited Epstein remarks resurface: Uncut video sparks outrage; social media users say 'Kamala should sue'
